Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell CarcinomaBusiness Wire • 06/02/26
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)Business Wire • 06/01/26
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin LymphomaBusiness Wire • 06/01/26
How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'Investors Business Daily • 05/29/26
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple MyelomaBusiness Wire • 05/29/26
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 05/27/26
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation PipelineBusiness Wire • 05/21/26
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global OperationsBusiness Wire • 05/20/26
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaborationCNBC • 05/15/26
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/14/26
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and NeuroscienceBusiness Wire • 05/14/26